#cannabisaficionado

Culture

Carly Barton: Pushing Boundaries as the UK’s First Medical Cannabis Patient

Published

on

Carly Barton
Photo | Carly Barton
Advertisement Back2Grow Advertisement

Carly Barton was 23 years old when she suffered a stroke. Anatomically, a stroke is caused by a temporary loss of blood flow to the brain. A simple explanation for an event that can alter the course of thinking, sensation, and perception for the duration of a patient’s life. For some, the aftermath of a stroke can lead to visual hallucinations, the loss of speech, or paralysis. Barton’s stroke, however, left its mark in the form of near continuous pain.

Several years later, it was this pain that landed Barton in a peculiar predicament — what does it take to get the National Health Service (NHS) to cover medical cannabis? Medical cannabis was legalized in the United Kingdom in November of 2018. Although a bit behind the times by North American standards, Home Secretary Sajid Javid called for “swift action” after hearing testimonies from patients and caregivers of those with debilitating and life-threatening illnesses.

True to his word, senior doctor’s were able to write prescriptions for cannabis as of November 01, 2018. And yet, only a few dozen patients have received official prescriptions for the herb. One of these patients is Barton, who has been forking over nearly 400 quid ($527 USD) per month. While politicians were moved to action by stories of epileptic children, it was Barton who received the first medical cannabis prescription in the UK.

And getting one was no easy task.

Gone to the Weeds

Pain is not uncommon after a stroke. While the body itself may not have experienced substantial harm, the brain can continue to send pain messages over and over again, like a noxious memory of an assault that cannot be erased. In Barton’s case, nerve damage garnered her the diagnoses of fibromyalgia and post-stroke neuropathy, which are most commonly treated with opiate pain killers.

“I was prescribed opiates in increasing doses for many years,” Barton explains, “and that leads to quite high doses of fentanyl and morphine.” A doped-induced delirium that lasted for six long years — housebound, imprisoned by one loud and omnipresent sensation, pain.

“Despite the fact that I was on opiates I was still experiencing a huge amount of pain, to the point where I couldn’t breathe, I couldn’t eat, I couldn’t sleep,” says Barton. “I was in my twenties and I needed help to dress and to cut my dinner up and just do really basic life stuff, and that was pretty horrible.”

Before her stroke, Barton was happily entangled in the spring of her life. A twenty-something art lecturer, she spent most of her time buzzing from welding projects to social affairs, a regular “pocket rocket” by her own terms. Still, even given the longstanding stereotypes about artists and cannabis, Barton was far from a stoner-girl hoping that the plant would unlock some hidden creative talent. “I didn’t think it was really me,” she says.

After the stroke, however, life came to a stand-still. In the years after the incident, Barton found herself stuck in a loop. “I was willing to literally try anything to get out of the cycle of just drinking excessive amounts of oral morphine and being on fentanyl all the time,” she says. It was at this point that a friend suggested that Barton try cannabis, a little homegrown which is illegal to cultivate in the UK.

“I had a lot of ideas, those notions, those preconceived notions about cannabis,” Barton explains. For one, she was worried about how the plant might affect her mental health, given that the herb has a reputation for worsening psychiatric ailments like depression and psychosis. And yet, after trying cannabis, Barton found her world turned right-side round within the span of 10 minutes.

Barton took a few puffs. “I went upstairs and my partner said to me, ‘are you alright?’ and I was saying, ‘something’s missing, something’s odd, something’s off.’ I couldn’t put any words to it,” she says. “And then I realized that the feeling that I had was just no pain.”

“It was so alien to me, not being able to feel any pain in my body, that I was confused as to what was happening. As soon as I realized that I couldn’t feel any pain head-to-toe, that was just like the moment when everything changed.”

“I haven’t touched a drop of morphine since that day.”

Becoming the First Medical Cannabis Patient in the UK

For six years, Barton had been stuck in a haze. Unable to perform simple everyday tasks, she spent most of her time lying in bed or lounging about the house. Cannabis, however, gave Barton her life back. It was time to spread the word. Impassioned by the extent of her recovery, Barton teamed up with other patients involved with United Patient’s Alliance, an advocacy group that services around 50,000 patients that currently rely on the black market to supply their medicine.

Founded in 2014, United Patient’s Alliance acts as a microphone for those who lack access to potentially life-saving cannabis medicines. The group lobbies government officials, provides a platform for patients to share their stories and organizes protests and other events across the United Kingdom. In the years leading up to medical cannabis legalization, advocates at the UPA worked tirelessly to connect patients with the policymakers that make decisions regarding their health.

In October of 2018, United Patient’s Alliance got its first major break — the Home Secretary committed to legalization. Barton, who had been consuming cannabis illegally to self-treat her pain condition, jumped at the opportunity to get a legitimate, legal prescription.

There was one major problem, however. Her doctors aligned with the National Health Service wouldn’t break out their prescription pads. Barton was the first medical cannabis patient in the UK to receive a prescription for the natural medicine. And yet, Barton had to fork over some serious cash for a private doctor in order to access medical cannabis. Even with the money, it certainly wasn’t easy.

“I spent months doing a kind of one-woman clinical trial and marking strains out of ten of the different symptoms and keeping a really thorough pain diary and really almost doing an observational trial on myself to determine what works and what didn’t,” she says. She turned these diligent records over to a private doctor, and it was only then that she received her prescription.

And yet, not all medical cannabis patients have the time, money, and where-with-all to keep such diligent records. “For a lot of patients in the UK who have been to doctors, we’ve had massive issues,” says Barton. “Since legalization, there are posts going up in pain clinics across the UK saying ‘don’t even ask about medical cannabis, we won’t be it to you’.”

UK Medical Cannabis Patients Pay an Arm and a Leg

The state of California first legalized medical cannabis in 1996 with Proposition 215. It took another two decades before cannabis reforms were introduced in the United Kingdom. In what some may see as a cruel bit of irony, the United Kingdom is currently the largest producer of medical cannabis in the entire world. In fact, a report from the United Nations International Narcotics Control Board declares that in 2016, over 95 tonnes of medical grade cannabis was produced in the UK, over 44 percent of the market share.

Unfortunately, none of this cannabis is going toward medical patients throughout the country. Instead, this high-quality medicine is used for research and scientific purposes by pharmaceutical companies. Meanwhile, patients like Barton are required to pay out-of-pocket for newly legalized cannabis medicines imported from Bedrocan, a medical cannabis company based in the Netherlands. Between import fees, the cost of the medicine, and the work with the private doctor, Barton raked up a £2,500 (3300 USD) fee in a three-month time period.

“The cost of it is ridiculous,” says Barton. “The cost of my prescription, just for the cannabis bit, was 400 quid for a month. But, once you’ve added on the import company’s cash that they want to import it here from Holland, that’s an extra £1,000. So, it works out at around £700 an ounce.”

Many patients with serious illnesses already face limited incomes and other medical fees, so the cost for private prescriptions creates a huge barrier for patients all over Brittin. For other medical treatments, the British government absorbs most of the cost via the National Health Service. Unfortunately, however, the NHS is not covering newly legalized cannabis medicines. This is something Barton and United Patients Alliance hope to change.

The biggest hurdle? Financial trusts.

“In the UK, each area has an individual trust and they deal with the funding that happens within that geographical area,” Barton explains. “They put limits on what drugs are going to be allowed to be prescribed within that geographical area.”

The goal of these trusts is to manage costs for government-funded health clinics. The money in these trusts comes from taxation, and each trust faces policy restrictions on the amount of money that can be spent on specific types of medicines and treatments.

“The trusts at the moment are refusing to allow doctors under their area to write medical cannabis prescriptions,” says Barton. “They’re literally terrified of opening the floodgates and there being massive ques and not being able to fund them all.”

Should the NHS begin to cover medical cannabis, patients would be able to access their medicine through government-funded sources. For the time being, however, patients are stuck between sticking with the black market or coughing up thousands for regular access to medical-quality products.

For the time being, the black market still seems like the better option.

Culture

Massachusetts Maps a Tentative 2027 Start for Cannabis Lounge Applications

The latest implementation plan separates lounge applications from event-organizer licensing, with local opt-in and operating approvals still central to the process.

Published

on

Lounge chairs and small tables beside indoor plants and glass railings

Massachusetts’s latest cannabis social-consumption implementation materials point to March 2027 for supplemental and hospitality license applications, followed by event-organizer applications in June. The timetable offers a clearer planning horizon for cannabis lounges and related businesses, but it is explicitly tentative. It is not an announcement that particular lounges will open in March or that current venues can begin allowing consumption.

The schedule appears in the Cannabis Control Commission’s November 12, 2026 public-meeting book. Anthony Martinelli reported the projected dates for The Marijuana Herald the same day. The primary presentation also lists unfinished guidance, application, technology and compliance work, explaining why a regulation already on the books has not yet become an operating market.

Three license classes, different settings

The commission’s January announcement established the basic structure. Supplemental licenses are intended to let qualifying existing marijuana establishments add on-site consumption at their business locations. Hospitality licenses create a route for qualifying applicants, including businesses that are not currently cannabis establishments. Event-organizer licenses address temporary consumption events.

Those categories matter because a café, an existing dispensary and a temporary gathering face different practical questions. A business looking for a permanent designated area is not necessarily pursuing the same license or operating plan as an organizer arranging an event. A general reference to cannabis lounges can obscure those distinctions.

The November presentation places supplemental and hospitality applications on the same target launch month, while giving event-organizer work a later milestone. Readers should keep those dates attached to the appropriate category rather than treating June as the timetable for every venue or March as a promise about every event.

Regulations and available applications are separate milestones

The commission says its social-consumption regulations took effect January 2, 2026. Its implementation project then had to develop the machinery that supports licensing: application materials, IT changes, responsible vendor training, inspection requirements, public information and coordination with municipalities.

That sequence explains an apparent contradiction in the public discussion. The existence of regulations does not mean a business can already obtain every necessary license. Equally, the future launch of an application process would not mean all applicants are immediately authorized to open their doors.

The November meeting materials list work on architectural and structural-change forms, consumer information cards, hospitality application and inspection requirements, and event-organizer compliance planning. They also identify review of four responsible-vendor-training applications. Those are implementation steps, not four approved cannabis lounges.

Local permission remains a gate

The commission’s municipal guidance says communities must opt in to social consumption through lawful local action. Municipalities can decide which license classes and consumption-area types to permit. Local authorization is therefore a substantive part of the process, rather than a detail that follows automatically from the state’s timetable.

The meeting materials include a municipal zoning-tracker form intended to help applicants and the public understand local authorization. The form expressly says that submitting information does not constitute commission approval of a specific establishment. A town appearing in a tracker should not be mistaken for an announcement that a named venue is ready to operate.

Host community agreements and other local requirements may also apply. For a prospective operator, that makes the useful planning questions local as well as statewide: what has the municipality authorized, what site requirements apply, and which approvals would still be necessary for the proposed business?

An equity-focused opening period

The commission’s published framework reserves the initial licensing opportunity for qualifying equity participants and specified smaller cannabis business categories. Its January announcement identifies Social Equity Program participants, Certified Economic Empowerment Priority Applicants, microbusinesses and craft marijuana cooperatives.

The announced exclusivity period runs for 36 months beginning when at least one licensee in each social-consumption class has received authorization to commence operations. It should not be described as a period that simply began when the regulations took effect in January. The trigger affects how the initial opportunity is understood.

What the next update needs to show

The November presentation identifies staffing capacity, technology requirements, competing initiatives and project-management demands as risks. Its target dates are therefore best read as planning milestones that depend on completing the remaining work, not guaranteed opening dates.

For readers following our Harvest Cup coverage, the broader point is also useful: a cannabis-oriented event and an authorized consumption setting are different things. A festival’s theme does not establish its permissions. Massachusetts’s developing system is intended to create a defined route for particular licensed settings.

The next meaningful evidence will be finalized applications and guidance, clear local authorization, and later notices allowing individual operators to commence operations. Until then, March and June provide a tentative map of the licensing project—not an invitation to assume that consumption is permitted at an existing café, hotel or event.

Illustrative hospitality-interior stock photograph; not a Massachusetts cannabis lounge or an approved consumption site. Photo: Tamara B / Unsplash.

Continue Reading

Culture

London’s Cannabis Industry Awards Put the People Behind the Sector in Focus

The Cannabis Industry Council’s November 11 London awards recognize work in patient care, science, advocacy and professional standards.

Published

on

Tables set with glassware and flowers in a banquet room

The Cannabis Industry Council’s awards dinner is scheduled for tonight, November 11, at the Honourable Artillery Company in London. Its cannabis connection is direct: the evening recognizes people working across the UK’s medical cannabis sector, from patient support and pharmacy to research, environmental practice and leadership.

The organizer’s current event page confirms the Wednesday date and venue. This is a preview of the published program, not a report from inside the ceremony. No award recipient should be inferred from a shortlist before the council announces the results.

Nominations for this edition closed in September. An event page that still describes nomination opportunities should not be read as a new chance to enter tonight’s awards; the current timetable and ceremony information take precedence.

Recognition extends beyond a company’s name

The council’s original nominations announcement says the awards recognize individuals rather than companies. That gives the evening a different emphasis from a product competition or a ranking of cannabis brands. The subject is the work people contribute to the sector.

That distinction matters in an industry where consumers often encounter a clinic, product or retailer before learning who supports the service. An individual award can draw attention to work that sits behind a familiar business name without establishing that the entire company is superior to every alternative.

The format also creates room for contributions that are difficult to summarize through sales figures. Helping someone navigate a service, improving a professional process or explaining evidence can matter even when those activities do not produce a headline about a large commercial deal.

Eight categories describe a broad professional community

The published categories include Unsung Hero, the Hannah Deacon Doctor of the Year, Contribution to Social Impact, Pharmacist of the Year, Contribution to Science, the Green Award, Customer Service and Industry Leader of the Year. Together, they place clinical, scientific and operational work alongside advocacy and environmental concerns.

The award named for Hannah Deacon recognizes patient care, according to the council’s description. The science category concerns contributions to understanding cannabis, while the environmental category addresses sustainability. Those are distinct kinds of achievement, and an award in one category should not be read as proof of an unrelated claim.

For example, recognition for customer service would not constitute a clinical trial, just as a scientific contribution would not tell a prospective patient everything about a clinic’s appointment process. The category is part of the meaning of the recognition, not a detail to drop from the eventual winners list.

The judges describe evidence as part of the standard

In the council’s introduction to its judging panel, judges emphasize demonstrated contribution, professional standards and delivery rather than visibility alone. The listed panel includes Professor Mike Barnes, Jamie Bartley, Frances Crewdson, Tom Gray, Nick Pateras, Callie Seaman, Luisa Searle and Heidi Whitman.

These are the organizers’ stated criteria and their panel’s perspectives. They explain what the competition aims to recognize; they are not an independent audit of every nominee’s work. Readers can value professional recognition while still asking what specific contribution led to it.

The useful follow-up after an awards night is therefore more than the name of the winner. What did the person do? Who benefited? What evidence supports the achievement? Those questions turn an honor into a story readers can understand rather than simply repeat.

A formal evening with a practical focus

The event is presented as an awards dinner with entertainment and networking. The current page invites guests to dress for the occasion but says a formal black-tie dress code is not required. Attendees should use the organizer’s current listing for access and practical details rather than assume an older ticket offer remains available.

That presentation places cannabis professionals in a familiar cultural setting: a shared evening recognizing peers. The interest lies in how a developing sector chooses to describe good work and which kinds of contribution it brings into public view.

Our preview of MEDICA’s cannabis-counseling workshop follows another professional gathering, with a different purpose and audience. Training, research and recognition are separate activities, but each can reveal what a cannabis-related professional community considers important.

Wait for the results, then look at the work

The council’s published timetable places the ceremony after the nomination and judging periods. The current story is that the event is scheduled to take place, not that a particular person has won. A results report will require an actual announcement from the organizer.

For now, the evening’s structure offers a clear view of the subjects being celebrated: patient-facing work, scientific understanding, responsible operations and leadership. The most meaningful coverage after the ceremony will connect those category names to concrete achievements, keeping the contribution in focus alongside the celebration.

Illustrative banquet photograph; not the HAC or the Cannabis Industry Awards. Photo: Filip Rankovic Grobgaard / Unsplash.

Continue Reading

Culture

Vermont Opens Its Cannabis Event Lottery Window November 16

A regional lottery will select retailers for the next stage of Vermont’s event-sales pilot, with local approval and detailed operating plans still required.

Published

on

Autumn trees and hills near Mount Mansfield in Stowe, Vermont

Vermont cannabis retailers will soon be able to enter a lottery for a pilot program that could move regulated sales beyond the conventional dispensary. The Cannabis Control Board says the submission window opens November 16 and closes November 30, 2026, with a regional drawing planned for its December 16 meeting.

The cannabis connection is the substance of the program: selected retailers can seek permission to administer off-site events where registered cannabis products are displayed and sold. That is a more limited proposition than an open-consumption festival. The adopted procedure expressly preserves Vermont’s prohibition on public cannabis consumption.

The board’s official events pilot page sets out the dates and application route. Its procedure adopted October 28 explains what applicants must demonstrate before a permit can become an actual event.

A lottery entry is not an event permit

The first step is a preliminary application from a qualified retail cannabis establishment. There is no fee to enter the lottery. The board nevertheless asks businesses to enter only after reviewing the requirements and deciding they have both the capacity and intention to host a compliant event.

The procedure divides the state into five regions and requires a retailer to apply within the region where it is located, for an event in that region. For each region, a final applicant is selected from qualified preliminary applicants by lottery. The procedure also allows first and second runners-up to be selected.

Selection leads to the full application stage, rather than automatically authorizing sales. That later application includes required documentation, standard-form municipal approval and a $500 application fee. Final approval is determined by a board vote. The procedure allows no more than ten event permits per year, a ceiling that should not be confused with a promise that ten events have already been approved.

Local approval and retail experience matter

An event can take place only in a municipality that has voted to authorize cannabis retail sales. The applicant must also obtain written approval for the planned event from the relevant municipal authority. That approval can include conditions addressing public protection, traffic and nuisance concerns.

Applicants must demonstrate good standing and tax compliance. The procedure’s definition includes at least six months of continuous, compliant operation, an appropriate compliance history and reliable recordkeeping. A newly imagined event concept, without the required retail credentials and operating capacity, is therefore not enough.

The operational burden also reaches the retailer’s existing shop. Except for the specified case of an event contiguous with the licensed retail location, a permit holder cannot conduct sales at its shop and the event simultaneously. Businesses weighing participation will need to consider staffing and the effect on normal operations.

Culture can be part of the setting

The procedure allows the board to authorize responsible integration with commercial and cultural offerings. It gives examples including musical artists and vendors serving food or nonalcoholic beverages. Vendors and their employees working at the event must be at least 21, and vendors must hold any other required permits or licenses.

Those possibilities do not remove the program’s boundaries. Settings that sell or furnish alcohol for on-premises consumption are unsuitable, as are settings that appeal to people under 21 or encourage the expectation that public cannabis consumption is authorized. The procedure also identifies activities requiring heightened coordination or judgment, such as the start of a sporting competition, as problematic contexts.

For readers following events such as The Harvest Cup in Massachusetts, the distinction is useful: a cannabis-oriented gathering and a government permit to sell cannabis are separate questions. Vermont’s pilot creates a specific approval route, not a general rule for every cultural event.

The practical plans behind a public event

Security and product-sale plans must explain how inventory, money, staff and access will be managed. The rules address preventing entry by intoxicated people and anyone under 21, protecting products from diversion, and keeping cannabis products out of general public view. They also require inventory tracking arrangements, including accurate records if connectivity is lost.

The product plan has a further market-access requirement: at least 40 percent must meet the procedure’s unaffiliated-product standard, applied by stock-keeping units within specified product categories. Medical cannabis products cannot be promoted or sold at an event. Liability insurance must cover the event location and activities.

For now, November’s deadline is a preparation milestone. No event date, location or participant list follows automatically from it. The next meaningful development will be the regional selection, followed by complete applications and board decisions that show what this tightly bounded experiment will look like in practice.

Stock landscape photograph of Stowe, Vermont; not a proposed or approved cannabis event site. Photo: Rafael Rodrigues / Unsplash.

Continue Reading

Trending

Join The Cannabis Aficionado Community!
Join the Cannabis Aficionado community and receive all of the most relevant news geared towards our sophisticated enthusiast community.
Loading

Copyright ©️ 2026 Cannabis Aficionado. Cannabis Aficionado is a registered trademark of CNM Inc. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service, Privacy Policy and Cookies Policy. People may receive compensation for some links to products and services. Offers may be subject to change without notice.